60 Degrees Pharmaceuticals, Inc. (SXTP)

NCM – Real Time Price. Currency in USD

1.50

+0.03 (2.04%)

At close: May 12, 2026, 4:00 PM EDT

1.47

-0.03 (-2.00%)

Pre-market: May 13, 2026, 5:26 AM EDT

03.04.2026

60 Degrees Pharmaceuticals Inc. (SXTP) Upgraded to Buy: Here's What You Should Know

60 Degrees Pharmaceuticals Inc. (SXTP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

31.03.2026

60 Degrees Pharmaceuticals Announces 2025 Annual Results

FY 2025 net product revenues increased 65% to $1,005,000 Current shelf capacity exhausted after raise of $4 million through an ATM facility WASHINGTON, March 31, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for vector-borne disease, reported today its financial results for the 2025 fiscal year ended December 31, 2025. Financial Highlights for the Fiscal Year Ended December 31, 2025: Net product revenues increased 65% from $607.6 thousand in 2024 to $1.0 million in 2025, driven by rising sales, price increases, and fewer returns.

18.03.2026

60 Degrees Pharmaceuticals Files New Dietary Ingredient Notification (NDIN) with FDA for Australian Chestnut Extract

60 Degrees files NDIN with FDA for Australian Chestnut Extract; May 25 decision deadline. FSU capsule license option expands commercialization strategy.

13.03.2026

What's Going On With 60 Degrees Pharmaceuticals On Friday?

60 Degrees Pharmaceuticals Inc. (NASDAQ: SXTP) shares are down during Friday's premarket session. This follows a 9.6% decline, closing at $2.91 on Thursday.

11.03.2026

60 Degrees Pharmaceuticals Announces All Patients Cured of Babesiosis After Tafenoquine Treatment in Expanded Use Clinical Trial

All three patients in 60 Degrees Pharma's expanded access study were cured of relapsing babesiosis after tafenoquine treatment, supporting guideline review

02.02.2026

60 Degrees Pharmaceuticals Expands Access to ARAKODA® with GoodRx Partnership

GoodRx to offer prescription savings of up to 30% for ARAKODA® (tafenoquine) Collaboration designed to lower patient out-of-pocket costs and expand the reach of Company's marketing strategy Partnership will improve the affordability of ARAKODA at over 70,000 pharmacies nationwide for people planning travel to malaria-endemic regions WASHINGTON, Feb. 02, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees Pharma” or the “Company”), a pharmaceutical company focused on developing new medicines for vector-borne disease, today announced a partnership with GoodRx (Nasdaq: GDRX), the leading platform for prescription savings in the U.S., to offer eligible consumers savings of up to 30% on ARAKODA® (tafenoquine). ARAKODA is the only FDA-approved, broad spectrum, once-weekly prescription malaria prevention on the U.S. market.

15.01.2026

60 Degrees Pharmaceuticals, Inc. Announces Approval of Reverse Stock Split Ratio

WASHINGTON, Jan. 15, 2026 (GLOBE NEWSWIRE) -- 60 Degree Pharmaceuticals, Inc. NASDAQ: SXTP; SXTPW) (“60 Degrees Pharma” or the “Company”), a pharmaceutical company focused on developing new medicines for vector-borne disease, today announced that it will effect a one-for-four (1:4) reverse stock split (the "reverse split") of its common stock, par value $0.0001 per share (the "Common Stock"), that will become effective on January 20, 2026, at 12:01 AM Eastern Time, before the opening of trading on The Nasdaq Capital Market ("Nasdaq"). 60 Degrees Pharma has requested that its Common Stock begin trading on January 20, 2026, on a post-reverse split basis on the Nasdaq under the existing symbol "SXTP".

Videos

No Data

There is no data to display

Press releases

31.03.2026

60 Degrees Pharmaceuticals Announces 2025 Annual Results

18.03.2026

60 Degrees Pharmaceuticals Files New Dietary Ingredient Notification (NDIN) with FDA for Australian Chestnut Extract

60 Degrees files NDIN with FDA for Australian Chestnut Extract; May 25 decision deadline. FSU capsule license option expands commercialization strategy.

11.03.2026

60 Degrees Pharmaceuticals Announces All Patients Cured of Babesiosis After Tafenoquine Treatment in Expanded Use Clinical Trial

All three patients in 60 Degrees Pharma's expanded access study were cured of relapsing babesiosis after tafenoquine treatment, supporting guideline review

02.02.2026

60 Degrees Pharmaceuticals, Inc. (SXTP)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

60 Degrees Pharmaceuticals, Inc. (SXTP)

60 Degrees Pharmaceuticals Inc. (SXTP) Upgraded to Buy: Here's What You Should Know

60 Degrees Pharmaceuticals Announces 2025 Annual Results

60 Degrees Pharmaceuticals Files New Dietary Ingredient Notification (NDIN) with FDA for Australian Chestnut Extract

What's Going On With 60 Degrees Pharmaceuticals On Friday?

60 Degrees Pharmaceuticals Announces All Patients Cured of Babesiosis After Tafenoquine Treatment in Expanded Use Clinical Trial

60 Degrees Pharmaceuticals Expands Access to ARAKODA® with GoodRx Partnership

60 Degrees Pharmaceuticals, Inc. Announces Approval of Reverse Stock Split Ratio

Videos

No Data

Press releases

60 Degrees Pharmaceuticals Announces 2025 Annual Results

60 Degrees Pharmaceuticals Files New Dietary Ingredient Notification (NDIN) with FDA for Australian Chestnut Extract

60 Degrees Pharmaceuticals Announces All Patients Cured of Babesiosis After Tafenoquine Treatment in Expanded Use Clinical Trial

60 Degrees Pharmaceuticals Expands Access to ARAKODA® with GoodRx Partnership

60 Degrees Pharmaceuticals Inc. (SXTP) Upgraded to Buy: Here's What You Should Know

60 Degrees Pharmaceuticals Announces 2025 Annual Results

60 Degrees Pharmaceuticals Files New Dietary Ingredient Notification (NDIN) with FDA for Australian Chestnut Extract

What's Going On With 60 Degrees Pharmaceuticals On Friday?

60 Degrees Pharmaceuticals Announces All Patients Cured of Babesiosis After Tafenoquine Treatment in Expanded Use Clinical Trial

60 Degrees Pharmaceuticals Expands Access to ARAKODA® with GoodRx Partnership

60 Degrees Pharmaceuticals, Inc. Announces Approval of Reverse Stock Split Ratio

Videos

No Data

Press releases

60 Degrees Pharmaceuticals Announces 2025 Annual Results

60 Degrees Pharmaceuticals Files New Dietary Ingredient Notification (NDIN) with FDA for Australian Chestnut Extract

60 Degrees Pharmaceuticals Announces All Patients Cured of Babesiosis After Tafenoquine Treatment in Expanded Use Clinical Trial

60 Degrees Pharmaceuticals Expands Access to ARAKODA® with GoodRx Partnership

Search stocks

60 Degrees Pharmaceuticals, Inc. (SXTP)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

60 Degrees Pharmaceuticals, Inc. (SXTP)

60 Degrees Pharmaceuticals Inc. (SXTP) Upgraded to Buy: Here's What You Should Know

60 Degrees Pharmaceuticals Announces 2025 Annual Results

60 Degrees Pharmaceuticals Files New Dietary Ingredient Notification (NDIN) with FDA for Australian Chestnut Extract

What's Going On With 60 Degrees Pharmaceuticals On Friday?

60 Degrees Pharmaceuticals Announces All Patients Cured of Babesiosis After Tafenoquine Treatment in Expanded Use Clinical Trial

60 Degrees Pharmaceuticals Expands Access to ARAKODA® with GoodRx Partnership

60 Degrees Pharmaceuticals, Inc. Announces Approval of Reverse Stock Split Ratio

Videos

No Data

Press releases

60 Degrees Pharmaceuticals Announces 2025 Annual Results

60 Degrees Pharmaceuticals Files New Dietary Ingredient Notification (NDIN) with FDA for Australian Chestnut Extract

60 Degrees Pharmaceuticals Announces All Patients Cured of Babesiosis After Tafenoquine Treatment in Expanded Use Clinical Trial

60 Degrees Pharmaceuticals Expands Access to ARAKODA® with GoodRx Partnership

60 Degrees Pharmaceuticals Inc. (SXTP) Upgraded to Buy: Here's What You Should Know

60 Degrees Pharmaceuticals Announces 2025 Annual Results

60 Degrees Pharmaceuticals Files New Dietary Ingredient Notification (NDIN) with FDA for Australian Chestnut Extract

What's Going On With 60 Degrees Pharmaceuticals On Friday?

60 Degrees Pharmaceuticals Announces All Patients Cured of Babesiosis After Tafenoquine Treatment in Expanded Use Clinical Trial

60 Degrees Pharmaceuticals Expands Access to ARAKODA® with GoodRx Partnership

60 Degrees Pharmaceuticals, Inc. Announces Approval of Reverse Stock Split Ratio

Videos

No Data

Press releases

60 Degrees Pharmaceuticals Announces 2025 Annual Results

60 Degrees Pharmaceuticals Files New Dietary Ingredient Notification (NDIN) with FDA for Australian Chestnut Extract

60 Degrees Pharmaceuticals Announces All Patients Cured of Babesiosis After Tafenoquine Treatment in Expanded Use Clinical Trial

60 Degrees Pharmaceuticals Expands Access to ARAKODA® with GoodRx Partnership